January 07, 2019
1 min read

Bimatoprost sustained-release implant reduces IOP in phase 3 study

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

A bimatoprost sustained-release implant reduced IOP by approximately 30% over 12 weeks in a second phase 3 study, Allergan announced in a press release.

The majority of patients with open-angle glaucoma or ocular hypertension in the 528-subject trial were also able to remain treatment-free for at least 1 year after the last implant was inserted, the release said.

“The data results of intracameral Bimatoprost SR were consistently demonstrated in two pivotal trials, highlighting the sustained, predictable and potentially sight-saving benefits of this exciting new approach in treating patients with glaucoma,” David Nicholson, Allergan chief research and development officer, said in the release. “We are particularly encouraged by the long-term efficacy results leading to an extended treatment-free period.”

Allergan plans to submit a new drug application to the FDA in the second half of 2019.